newsfilter
← Latest News
GlobeNewswire·

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), is on track for the end of the first quarter